

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Our Mission, Vision & Treatment](#)
[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)


[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Darren R. Feldman, MD

[Genitourinary Medical Oncologist](#) ([#about-me](#))



Areas of Expertise

Conditions I Treat

- Genitourinary cancers and conditions
- Testicular cancer
- Kidney (renal cell) cancer and conditions

My Specialties

- Combination therapy
- Immunotherapy
- Targeted therapy

[View more expertise](#) ([#about_specialties](#))



[Dr. Feldman's Office Information](#) ([#contact-and-location](#))



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9068](#)

[Make an appointment](#)

Get to Know Me

I am a medical oncologist who cares for people with genitourinary cancer. I specialize in treating [testicular cancer \(germ cell tumors\)](#) and [kidney cancer \(renal cell carcinoma\)](#).

This provider is part of a team that was ranked [#1 in the nation for Urology Cancer Care](#) this year by *U.S. News & World Report*.

My research centers on developing new drugs or drug combinations for people with these cancers. I also lead national and international clinical trials for people with genitourinary cancer.

Read more +

What I Do at MSK

I'm a genitourinary (GU) medical oncologist, which is a cancer doctor who specializes in genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.

- Section Head, Germ Cell Cancer

Areas of Expertise

Conditions I Treat

- Genitourinary cancers and conditions
- Testicular cancer
- Kidney (renal cell) cancer and conditions

My Specialties

- Combination therapy
- Immunotherapy
- Targeted therapy
- Clinical trials

Education & Honors

Education

- MD, University of Maryland School of Medicine

Residencies

- Internal Medicine - New York University School of Medicine
- Chief Resident, Department of Medicine - Memorial Sloan Kettering Cancer Center

Fellowships

- Oncology/Hematology - Memorial Sloan Kettering Cancer Center

Board Certifications

- Medical Oncology
- Hematology

Awards and Honors

- Castle Connolly: America's Top Doctor (2026)
- Castle Connolly: America's Top Doctor (2025)
- Castle Connolly: America's Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2014, 2016-2020)
- John Mendelsohn Housestaff Teaching Award, Department of Medicine, Memorial Sloan Kettering Cancer Center (2005-2006)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](#) .

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call [646-497-9068](#) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

Contact and Location


Office Phone

 [646-888-4740](tel:646-888-4740)

Location

 New York, NY

[Sidney Kimmel Center for Prostate and Urologic Cancers](#)

 353 East 68th Street
New York, NY 10065
[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .


Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Genitourinary Oncology Service doctors](https://www.mskcc.org/doctor#f:Departments=[Medicine,Division of Solid Tumor Oncology,Genitourinary Oncology Service]) ([https://www.mskcc.org/doctor#f:Departments=\[Medicine,Division of Solid Tumor Oncology,Genitourinary Oncology Service\]](https://www.mskcc.org/doctor#f:Departments=[Medicine,Division of Solid Tumor Oncology,Genitourinary Oncology Service]))

Clinical Trials

- Clinical Trials Investigated by Dr. Feldman
- [A Phase 3 Study Assessing the Addition of Tivozanib to Pembrolizumab Immunotherapy After Surgery for Kidney Cancer](#)
- [A Phase III Study of Accelerated versus Standard Chemotherapy for Patients with Intermediate- and Poor-Risk Metastatic Germ Cell Tumors](#)

- 

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

[Search clinical trials \(https://www.mskcc.org/cancer-care/clinical-trials\)](https://www.mskcc.org/cancer-care/clinical-trials)

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. *J Clin Oncol*. 2016 Jul 20;34(21):2478-83.

Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. *J Clin Oncol*. 2016 Nov;34(32):3846-3853.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. *J Clin Oncol*. 2016 Nov;34(33):4000-4007.

Read more +

Visit PubMed for a full listing of Dr. Feldman's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%28%22neoplasms%22%5BMH%5D%20OR%20cancer%5BTW%5D%29%20OR%20sloan-kettering%20AND%20Feldman%20DR%5BAU%5D%29%20AND%20%28%222006%22%5BPDat%5D%3A%223000%22%5BPDat%5D%29>)

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external

entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Darren R. Feldman discloses the following relationships and financial interests:

- BioNTech
Professional Services and Activities
- Exelixis
Professional Services and Activities
- UptoDate
Intellectual Property Rights

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center